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| INTRODUCTION
Prostate cancer is one of the most common cancers among men.
When it is detected and treated at its early stage, disease control and patient survival are relatively high. 1 Proton therapy is one of the treatment modalities used in prostate cancer radiotherapy. Sharp distal dose fall-off and less integral dose are a couple of its intrinsic advantages. 2 There are three commonly used proton treatment delivery techniques: double scattering (DS), uniform scanning (US), and pencil-beam scanning (PBS). [3] [4] [5] PBS prostate treatment is available at some of the new proton therapy institutions; DS and US deliveries are used by some proton therapy clinics. DS and US deliver the radiation dose to the target as a spread-out Bragg peak (SOBP). 6 PBS treatment plans are inversely optimized and can be delivered through single-field uniform dose plans or multi-field optimizations plans. In DS delivery, the SOBP covers the entire clinical target volume (CTV) at a given instance (0.1 s interval for IBA system). Target intrafraction motion will cause CTV dose degradation due to target movement outside the SOBP or beam's eye view. On the other hand, in US and PBS delivery, energy layers are delivered in a distal to proximal direction; thus, there is a temporal-spatial variation of the radiation dose inside the treated volume during the treatment process. This interplay effect of prostate intrafraction motion on PBS treatment was simulated and studied by Tang et al. 7 In this study, the effects of prostate motion on dose delivery during DS and US treatment were simulated and studied using real patient prostate traces. The prostate CTV individual fraction dose distribution and 14-fraction cumulative dose distribution were obtained using 17 patient intrafraction motion traces in the 2 Gy per fraction simulations. For prostate stereotactic body radiotherapy (SBRT), five fractions with 7.25 Gy per fraction were simulated; both individual fraction and five fraction cumulative dose distributions were obtained. We evaluated how prostate dose distributions are affected by the interplay between prostate motion and the energy-layer delivery.
| MATERIALS AND METHODS

2.A | Proton therapy delivery techniques
At the University of Florida Health Proton Therapy Institute (UFHPTI), IBA (Brussels, Belgium) proton treatment machines 8 When DS treatment is delivered, the range modulator rotates at 600 RPM. Depending on the modulation width, the proton beam current is turned on for a predetermined portion of the modulator track. Each step on the modulator track corresponds to an energy layer to be delivered. With the second scatter in the beamline to create a flat axial-beam profile, the entire SOBP is delivered in one revolution of the range modulator, which takes 0.1 s. Thus, at a given instance, an entire stationary target can be covered by the SOBP. In US treatment delivery, the second scatter is replaced by two sets of beam scanning magnets in the two orthogonal directions perpendicular to the beam axis. Each energy layer is delivered through magnetic sweeping of the beam spot in the two directions.
At UFPTI, the scanning frequency is 3 Hz in the gantry rotation axis direction and 30 Hz in its orthogonal direction. There is multiple repainting of each energy layer. Furthermore, the range modulator is static during the delivery of each energy layer and only rotates when beam is off between the deliveries of the energy layers. The energy layers are delivered sequentially from the most distal to the most proximal ones. At a given instance, either a nonuniform dose is delivered to the entire target (when the most distal layer is delivering) or only part of the target receives the radiation dose (all other layers).
Using the US technique, the maximum beam range is increased to 32.4 cm and the treatable field size is increased to 30 cm by 40 cm.
Therefore, the US technique can treat some deep-seated tumors as well as extremely large targets. However, compared to DS delivery, US delivery is potentially more susceptible to the spatial-temporal interplay due to target motion and nonuniform target dose delivery.
When the target motion is in the beam direction, part of the target can be over-irradiated by different layers, or it can be underdosed by missing irradiation from an energy layer, depending on the motion characteristics and layer-delivery timing. 9 
2.B | Prostate traces
Prostate-motion traces acquired using a Calypso electromagnetic transponder tracking system of 17 patients were obtained from the Virginia Commonwealth University Department of Radiation Oncology with institutional review board (IRB) approval. The Calypso 4D localization system localizes and tracks electromagnetic transponders implanted in the patient's target volume. The overall system components and operating principles have been described by Balter et al. 10 This system can measure the target position with submillimeter accuracy at a rate of 10 Hz. The intrafraction prostate traces were from patients treated with intensity-modulated radiation therapy (IMRT). The dose fractionations were slightly different among the patients, but they ranged from 32 to 39 fractions with total doses ranging from 72 to 78 Gy. Prostate motion tracking time was different among patients as well as between different treatment fractions for the same patient and ranged from 4 to 10 min. The patient prostate motion characteristics varied from patient to patient; however, each patient exhibited some consistency in intrafraction motion characteristics among different fractions. Patient prostate motion exhibited slow drifts, transient excursions, or persistent deviations from the initial setup position. 11 Detailed prostate intrafraction motion information can be found in reference 10. In summary, nine out of 17 patients have at least 10% of the tracked time that their prostate moved beyond 3 mm (three-dimensional distance) from initial setup position; three out 17 patients have at least 10% of the tracked time that their prostate moved beyond 5 mm (three-dimensional distance) from initial setup position; one out 17 patients has at least 10% of the tracked time that their prostate moved beyond 7 mm (three-dimensional distance) from initial setup position. It was also observed that there is a relatively strong positive correlation between the prostate superior-inferior (SI) direction motion and its anterior-posterior (AP) motion. One of the methods to quantify the intrafraction motion is to calculate its systematic and random components from the patient cohort. The systematic component is calculated as the standard deviation of population-average prostate displacement. The random component is calculated as the rootmean-square of the patient-specific standard deviation of prostate displacement. Data analysis of the motion traces showed that the systematic components of prostate intrafraction motion were 0.3, 0.5 and 0.6 mm for left-right (LR), SI and AP directions, respectively; the random components of prostate intrafraction motion were 0.7, 1.4 and 1.9 mm for left-right (LR), SI and AP directions, respectively.
2.C | Prostate proton treatment simulation
At UFPTI, left and right lateral or lateral-oblique beams are often used to treat prostate patients. 12 All of these patients have saline However, the DVH of simulated US treatment showed that there are more hot (overdose i.e. V110> 2%) and cold (underdose i.e. D95% < 95%) spots in the CTV. For the simulated DS treatment, there was mainly underdosing of the CTV. Greater maximum values of V110 for US deliveries indicated hotter spots (more overdosing) inside CTV than those of DS deliveries. Larger standard deviations of the DVH points for US deliveries indicated that there is larger CTV dosimetric uncertainties compared to DS deliveries with the same intrafraction prostate motion. However, student t-test indicated that there are no statistically significant dose differences between the DS and US treatments except for values of V110. Regular-fractionation prostate radiotherapy usually delivers treatment in more than 30 fractions. Some of the hot and cold spots for the CTV dose in individual fractions can be washed out after many fractions of treatment. Table 2 shows DVHs for the 14- Table 3 and 4 from the SBRT simulations of the individual fraction and the cumulative 5 fraction treatment.
2.D | Prostate motion dosimetry
| DISCUSSION
Many investigators have studied target intrafraction motion and its dosimetric impact on CTV dose coverage in photon and proton radiation therapy. [15] [16] [17] [18] [19] [20] This study focused on the simulation of DS and US proton treatment using real patients' prostate intrafraction Even though the proton treatment simulation incorporated the prostate motion and energy layer delivery timing to investigate the impact of intrafraction motion on prostate CTV dosimetry, not all the details of the US delivery were incorporated in the simulation.
For example, the scanning frequencies of 3 Hz in the gantry rotation axis direction and 30 Hz in its orthogonal direction as well as the repainting of each energy layer were not simulated. We believe that rapid-beam spot scanning and repainting of each energy layer equivalently created a quasi-instantaneous dose cloud for each energy layer. Thus, in US delivery simulation, moving the prostate through the dose matrix of each energy layer based on its time weight is dosimetrically adequate and accurate.
| CONCLUSION
In this study, we simulated both DS and US proton treatment of prostate using real-patient prostate-motion traces and evaluated dosimetric impact of intrafraction motion on both delivery techniques.
The fraction dose analyses indicated that CTV dose degradation due to prostate intrafraction motion is patient and fraction specific. Severe intrafraction prostate motion can cause CTV hot and cold spots in US treatments, whereas it only causes CTV underdosing in DS treatments. However, no statistically significant dose differences were observed between the two treatment delivery techniques. The cumulative dose of several simulated treatment fractions showed that the magnitude of the CTV dose degradation was reduced and generally lies within a clinically acceptable range from planned dose distributions. Nevertheless, the effects of target intrafraction motion can be a concern for other, more dynamic targets.
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